Cargando…
A novel SARS-CoV-2 subunit vaccine engineered on an immune-activating platform technology
While there are several SARS-CoV-2 vaccines currently available, additional options must be provided that are safe, effective, and affordable for the entire global population. We have developed a novel immune activating platform technology that will fill this need. This recombinant platform protein...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9721441/ https://www.ncbi.nlm.nih.gov/pubmed/35801956 http://dx.doi.org/10.1080/21645515.2022.2062971 |